|
Jul 16
|
Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15
|
|
Jun 27
|
Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial
|
|
Jun 25
|
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
|
|
Jun 25
|
Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty l...
|
|
Jun 16
|
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
|
|
Feb 28
|
Psychedelic: GH Research, Compass Pathways report earnings results
|
|
Feb 26
|
Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment
|
|
Feb 18
|
Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment
|
|
Feb 11
|
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
|
|
Jan 2
|
Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain
|
|
Jul 26
|
Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
|
|
Jun 26
|
Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety
|
|
May 21
|
Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention
|
|
Mar 20
|
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
|
|
Mar 18
|
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
|
|
Dec 28
|
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
|
|
Oct 16
|
Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
|
|
Aug 10
|
Silo Pharma Engages Clarivate for Intellectual Property and Patent Management
|
|
Aug 8
|
Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders
|